Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 06 November 2020

Schizophrenia: Epidemiology, Causes, Neurobiology, Pathophysiology, and Treatment

Kevin Volkan

California State University Channel Islands (USA), Community Memorial Health System (USA)

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 487-521

Keywords: Schizophrenia, Autoimmunity, Brain Structure, Antipsychotic Medication, Neuromodulation, Psychotherapy


Schizophrenia is a severe mental illness that has devastating consequences for those who suffer from the disorder. The epidemiology of schizophrenia indicates that it occurs relatively often, in many different contexts, and in conjunction with other disorders, decreasing quality of life and causing premature death. There has been an enormous amount of research into the causes of schizophrenia and there is now have a much better understanding of the genetic, environmental, and psychological factors that contribute to the disease. While there are numerous ways to understand and conceptualize schizophrenia, a unified picture of the neurobiology, changes in brain structure, cognitive and social-cognitive impairments related to the disorder has yet to emerge. Convulsive therapies and psychosurgery were used unsuccessfully, indiscriminately and without scientific validation in the past to treat schizophrenia. Medical advances including advanced imaging technology have now provided the ability to perform specifically focused neuromodulation and psychosurgery in severe and treatment resistant cases of schizophrenia. While still at a preliminary stage, these approaches have the potential to yield effective treatments in the future. For the last 70 years antipsychotic medication has become the prevailing treatment for schizophrenia. However, many people suffering from the disorder have trouble with side-effects and adhering to a regimen of antipsychotic medication. Newer pharmacological agents are being developed and include not only novel antipsychotic drugs, but anti-inflammatory and immunomodulating agents as well. These new agents, used either alone or in combination, have the potential to improve outcomes for people suffering from schizophrenia. Nevertheless, conclusively better pharmacotherapies will likely not arise until there is better understanding of the pathophysiology underlying schizophrenia. After the development of antipsychotic medication, psychotherapeutic methods for treating schizophrenia fell out of favor, but there is currently some reversal of this trend. The use of newer psychotherapies and modified forms of older therapeutic treatments are not only targeting the symptoms of schizophrenia but are also now focusing on recovery from the disorder. These newer approaches as well as efforts at preventing schizophrenia show promise in reducing the suffering caused by this disease.


  1. Adams, D. D., Knight, J. G., & Ebringer, A. (2012). The autoimmune model of schizophrenia. ISRN Psychiatry, 2012, 758072.

  2. Agarwal, V., Abhijnhan, A., & Raviraj, P. (2007). Ayurvedic medicine for schizophrenia. The Cochrane Database of Systematic Reviews, 4, CD006867.

  3. Agbeli, M. O. (2020). Reducing antipsychotic medication use in long-term care settings (2020-04052-126; Issues 5-A). ProQuest Information & Learning.

  4. Akhtar, S., & Volkan, V. D. (2005). Mental zoo: Animals in the human mind and its pathology. International Universities Press.

  5. Albert, N., Randers, L., Allott, K., Jensen, H. D., Melau, M., Hjorthøj, C., & Nordentoft, M. (2019). Cognitive functioning following discontinuation of antipsychotic medication A naturalistic sub-group analysis from the OPUS II trial. Psychological Medicine, 49(7), 1138–1147.

  6. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 (5 edition). American Psychiatric Publishing.

  7. Angyal, A. (1950). The psychodynamic process of illness and recovery in a case of catatonic schizophrenia. Psychiatry: Journal for the Study of Interpersonal Processes, 13, 149–165.

  8. Arnaiz, A., Zumárraga, M., Díez-Altuna, I., Uriarte, J. J., Moro, J., & Pérez-Ansorena, M. A. (2011). Oral health and the symptoms of schizophrenia. Psychiatry Research, 188(1), 24–28.

  9. Ashcroft, K., Kingdon, D. G., & Chadwick, P. (2012). Persecutory delusions and childhood emotional abuse in people with a diagnosis of schizophrenia. Psychosis: Psychological, Social and Integrative Approaches, 4(2), 168–171.

  10. Azrin, S. T., Goldstein, A. B., & Heinssen, R. K. (2015). Early intervention for psychosis: The Recovery After an Initial Schizophrenia Episode project. Psychiatric Annals, 45(11), 548–553.

  11. B, S., & Tk, C. (2014). Role of C-reactive protein in schizophrenia: An overview. Psychiatry Research, 216(2), 277–285.

  12. Barkan, T., Peled, A., Modai, I., Barak, P., Weizman, A., & Rehavi, M. (2006). Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients. European Neuropsychopharmacology, 16(8), 572–579.

  13. Barrowclough, C., Haddock, G., Lobban, F., Jones, S., Siddle, R., Roberts, C., & Gregg, L. (2006). Group cognitive-behavioural therapy for schizophrenia. British Journal of Psychiatry, 189(6), 527–532.

  14. Baumeister, A. A., & Francis, J. L. (2002). Historical development of the dopamine hypothesis of schizophrenia. Journal of the History of the Neurosciences, 11(3), 265–277.

  15. Beraki, S., Aronsson, F., Karlsson, H., Ögren, S. O., & Kristensson, K. (2005). Influenza A virus infection causes alterations in expression of synaptic regulatory genes combined with changes in cognitive and emotional behaviors in mice. Molecular Psychiatry, 10(3), 299–308.

  16. Bhugra, D. (2000). Migration and schizophrenia. Acta Psychiatrica Scandinavica, 102, 68–73.

  17. Bonnigal-Katz, D. (2019). Psychosis Therapy Project: A psychoanalytic project in the community. British Journal of Psychotherapy, 35(4), 586–589.

  18. Boydell, J., Van Os, J., Lambri, M., Castle, D., Allardyce, J., McCreadie, R. G., & Murray, R. M. (2003). Incidence of schizophrenia in south-east London between 1965 and 1997. British Journal of Psychiatry, 182(1), 45–49.

  19. Brakoulias, V., Starcevic, V., Albert, U., Arumugham, S. S., Bailey, B. E., Belloch, A., Borda, T., Dell’Osso, L., Elias, J. A., Falkenstein, M. J., Ferrao, Y. A., Fontenelle, L. F., Jelinek, L., Kalogeraki, L., Kay, B., Laurito, L. D., Lochner, C., Maina, G., Marazziti, D., … Fineberg, N. A. (2019). Treatments used for obsessive-compulsive disorder-An international perspective. Human Psychopharmacology, 34(1), e2686.

  20. Brambilla, P., & Tansella, M. (2007). Can neuroimaging studies help us in understanding the biological causes of schizophrenia? International Review of Psychiatry, 19(4), 313–314.

  21. Braslow, J. T. (1999). History and evidence-based medicine: Lessons from the history of somatic treatments from the 1900s to the 1950s. Mental Health Services Research, 1(4), 231–240.

  22. Bray, I., Waraich, P., Jones, W., Slater, S., Goldner, E. M., & Somers, J. (2006). Increase in schizophrenia incidence rates: Findings in a Canadian cohort born 1975-1985. Social Psychiatry and Psychiatric Epidemiology, 41(8), 611–618.

  23. Bresnahan, M., Menezes, P., Varma, V., & Susser, E. (2003). Geographical variation in incidence, course and outcome of schizophrenia: A comparison of developing and developed countries. The Epidemiology of Schizophrenia., 18–33.

  24. Brown, A. S., & McGrath, J. J. (2011). The Prevention of Schizophrenia. Schizophrenia Bulletin, 37(2), 257–261.

  25. Brown, A. S., & Patterson, P. H. (2011). Maternal Infection and Schizophrenia: Implications for Prevention. Schizophrenia Bulletin, 37(2), 284–290.

  26. Brown, A. S., Schaefer, C. A., Quesenberry, C. P. Jr., Shen, L., & Susser, E. S. (2006). No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? American Journal of Psychiatry, 163(12), 2178–2180.

  27. Brown, S., Inskip, H., & Barraclough, B. (2000). Causes of the excess mortality of schizophrenia. British Journal of Psychiatry, 177, 212–217.

  28. Buckley, L., & Pettit, T. (2007). Supportive therapy for schizophrenia. Schizophrenia Bulletin, 33(4), 859–860.

  29. Buka, S. L., Cannon, T. D., Torrey, E. F., & Yolken, R. H. (2008). Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biological Psychiatry, 63(8), 809–815.

  30. Burns, J. (2007). The Descent of Madness: Evolutionary Origins of Psychosis and the Social Brain (1 edition). Routledge.

  31. Butler, P. D., Susser, E. S., Brown, A. S., Kaufmann, C. A., & Gorman, J. M. (1994). Prenatal nutritional deprivation as a risk factor in schizophrenia: Preclinical evidence. Neuropsychopharmacology, 11(4), 227–235.

  32. Byrne, M., Agerbo, E., Bennedsen, B., Eaton, W. W., & Mortensen, P. B. (2007). Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study. Schizophrenia Research, 97(1), 51–59.

  33. Capasso, R. M., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & St. Sauver, J. (2008). Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. Schizophrenia Research, 98(1), 287–294.

  34. Caruso, J. P., & Sheehan, J. P. (2017). Psychosurgery, ethics, and media: A history of Walter Freeman and the lobotomy. Neurosurgical Focus, 43(3), E6.

  35. Casey, D. E., Haupt, D. W., Newcomer, J. W., Henderson, D. C., Sernyak, M. J., Davidson, M., Lindenmayer, J.-P., Manoukian, S. V., Banerji, M. A., Lebovitz, H. E., & Hennekens, C. H. (2004). Antipsychotic-lnduced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients with Schizophrenia. Journal of Clinical Psychiatry, 65, 4–18.

  36. Castle, D. J., & Morgan, V. (2008). Epidemiology. Clinical Handbook of Schizophrenia., 14–24.

  37. Chan, S. K. W., Hui, C. L. M., Chang, W. C., Lee, E. H. M., & Chen, E. Y. H. (2019). Ten-year follow up of patients with first-episode schizophrenia spectrum disorder from an early intervention service: Predictors of clinical remission and functional recovery. Schizophrenia Research, 204, 65–71.

  38. Chaudhry, I. B., Husain, N., ur Rahman, R., Husain, M. O., Hamirani, M. M., Kazmi, A., Baig, S., Haddad, P. M., Buch, M. H., Qureshi, I., Mehmood, N., Kiran, T., Fu, B., Afsar, S., & Deakin, B. (2015). A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: Study protocol for a randomised controlled trial. Trials, 16, 9.

  39. Cheniaux, E., Landeira-Fernandez, J., Telles, L. L., Lessa, J. L. M., Dias, A., Duncan, T., & Versiani, M. (2008). Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood. Journal of Affective Disorders, 106(3), 209–217.

  40. Chiu, V. W., Ree, M., Janca, A., Iyyalol, R., Dragovic, M., & Waters, F. (2018). Sleep profiles and CBT-I response in schizophrenia and related psychoses. Psychiatry Research, 268, 279–287.

  41. Chwastiak, L. A., & Tek, C. (2009). The unchanging mortality gap for people with schizophrenia. The Lancet, 374(9690), 590–592.

  42. Cowan, H. R. (2020). Is schizophrenia research relevant during the COVID-19 pandemic? Schizophrenia Research.

  43. Cullen, A. E., Holmes, S., Pollak, T. A., Blackman, G., Joyce, D. W., Kempton, M. J., Murray, R. M., McGuire, P., & Mondelli, V. (2019). Associations Between Non-neurological Autoimmune Disorders and Psychosis: A Meta-analysis. Biological Psychiatry, 85(1), 35–48.

  44. Dalman, C., Allebeck, P., Gunnell, D., Harrison, G., Kristensson, K., Lewis, G., Lofving, S., Rasmussen, F., Wicks, S., & Karlsson, H. (2008). Infections in the CNS during childhood and the risk of subsequent psychotic illness: A cohort study of more than one million Swedish subjects. American Journal of Psychiatry, 165(1), 59–65.

  45. D’Astous, M., Cottin, S., Roy, M., Picard, C., & Cantin, L. (2013). Bilateral stereotactic anterior capsulotomy for obsessive-compulsive disorder: Long-term follow-up. Journal of Neurology, Neurosurgery, and Psychiatry, 84(11), 1208–1213.

  46. Davenport, S., Hobson, R., & Margison, F. (2000). Treatment development in psychodynamic-interpersonal psychotherapy (Hobson’s ’Conversational Model’) for chronic treatment resistant schizophrenia: Two single case studies. British Journal of Psychotherapy, 16(3), 287–302.

  47. Davis, J. M., & Leucht, S. (2008). Has research informed us on the practical drug treatment of schizophrenia? Schizophrenia Bulletin, 34(3), 403–405.

  48. De Luca, V., Zai, G., Tharmalingam, S., de Bartolomeis, A., Wong, G., & Kennedy, J. L. (2006). Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia. European Neuropsychopharmacology, 16(4), 268–271.

  49. De Masi, F. (2020). Psychosis and analytic therapy: A complex relationship. The International Journal of Psychoanalysis, 101(1), 152–168.

  50. Dean, B., Hussain, T., Scarr, E., Pavey, G., & Copolov, D. L. (2001). Extended treatment with typical and atypical antipsychotic drugs: Differential effects on the densities of dopamine D-sub-2-like and GABA-sub(A) receptors in rat striatum. Life Sciences, 69(11), 1257–1268.

  51. Dean, B., Pavey, G., Thomas, D., & Scarr, E. (2006). Cortical serotonin-sub(7, 1D) and -sub(1F) receptors: Effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophrenia Research, 88(1), 265–274.

  52. Dean, K., Bramon, E., & Murray, R. M. (2003). The causes of schizophrenia: Neurodevelopment and other risk factors. Journal of Psychiatric Practice, 9(6), 442–454.

  53. Dickerson, F., Boronow, J., Stallings, C., Origoni, A., & Yolken, R. (2007). Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality. Schizophrenia Bulletin, 33(3), 737–740.

  54. Dickerson, F., Kirkpatrick, B., Boronow, J., Stallings, C., Origoni, A., & Yolken, R. (2006). Deficit schizophrenia: Association with serum antibodies to cytomegalovirus. Schizophrenia Bulletin, 32(2), 396–400.

  55. Dickerson, F., Severance, E., & Yolken, R. (2017). The microbiome, immunity, and schizophrenia and bipolar disorder. Brain, Behavior, and Immunity, 62, 46–52.

  56. Dickson, H., Hedges, E. P., Ma, S. Y., Cullen, A. E., MacCabe, J. H., Kempton, M. J., Downs, J., & Laurens, K. R. (2020). Academic achievement and schizophrenia: A systematic meta-analysis. Psychological Medicine.

  57. Dion, G. L., & Dellario, D. (1988). Symptom subtypes in persons institutionalized with schizophrenia: Comparison of demographics, outcome and functional skills. Rehabilitation Psychology, 33(2), 95–104.

  58. Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Research International, 2014, 656370.

  59. dosReis, S., Johnson, E., Steinwachs, D., Rohde, C., Skinner, E. A., Fahey, M., & Lehman, A. F. (2008). Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia. Schizophrenia Research, 101(1), 304–311.

  60. Downing, D. L., & Mills, J. (2018). Outpatient Treatment of Psychosis: Psychodynamic Approaches to Evidence-Based Practice. Routledge.

  61. Dully, H., & Fleming, C. (2007). My Lobotomy. Crown.

  62. Dykxhoorn, J., Hollander, A.-C., Lewis, G., Magnusson, C., Dalman, C., & Kirkbride, J. B. (2019). Risk of schizophrenia, schizoaffective, and bipolar disorders by migrant status, region of origin, and age-at-migration: A national cohort study of 18 million people. Psychological Medicine, 49(14), 2354–2363.

  63. Eecke, W. V. (2019). How Does Psychoanalysis Work with Persons Afflicted By Schizophrenia? Journal of Psychology & Psychotherapy, 9(5), 1–5.

  64. Enger, C., Weatherby, L., Reynolds, R. F., Glasser, D. B., & Walker, A. M. (2004). Serious Cardiovascular Events and Mortality Among Patients with Schizophrenia. Journal of Nervous and Mental Disease, 192(1), 19–27.

  65. Fairbairn, W. R. D. (1941). A revised psychopathology of the psychoses and psychoneuroses. The International Journal of Psychoanalysis, 22, 250–270.

  66. Fakra, E., Salgado-Pineda, P., Delaveau, P., Hariri, A. R., & Blin, O. (2008). Neural bases of different cognitive strategies for facial affect processing in schizophrenia. Schizophrenia Research, 100(1), 191–205.

  67. Fan, J. B., & Sklar, P. (2005). Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Molecular Psychiatry, 10(10), 928–938.

  68. Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Huang, H., Oishi, K., Mori, S., Smee, D. F., Pearce, D. A., Winter, C., Sohr, R., & Juckel, G. (2008). Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: Implications for genesis of neurodevelopmental disorders. Schizophrenia Research, 99(1), 56–70.

  69. Fearon, P., Kirkbride, J. B., Morgan, C., Dazzan, P., Morgan, K., Lloyd, T., Hutchinson, G., Tarrant, J., Fung, W. L. A., Holloway, J., Mallett, R., Harrison, G., Leff, J., Jones, P. B., & Murray, R. M. (2006). Incidence of schizophrenia and other psychoses in ethnic minority groups: Results from the MRC AESOP Study. Psychological Medicine, 36(11), 1541–1550.

  70. Ferenczi, S., & Jones, E. (1916). Some Clinical Observations on Paranoia and Paraphrenia. In Contributions to psycho-analysis. (2006-03526-011; pp. 238–249). Richard G. Badger.

  71. Findlay, L. J. (2015). Decision-making processes and health behaviors among adults diagnosed with schizophrenia(2015-99060-062; Issues 9-B(E)). ProQuest Information & Learning.

  72. Flegr, J., & Kuba, R. (2016). The relation of Toxoplasma infection and sexual attraction to fear, danger, pain, and submissiveness. Evolutionary Psychology, 14(3).

  73. Fonseca, L., Diniz, E., Mendonça, G., Malinowski, F., Mari, J., Gadelha, A., Fonseca, L., Diniz, E., Mendonça, G., Malinowski, F., Mari, J., & Gadelha, A. (2020). Schizophrenia and COVID-19: Risks and recommendations. Brazilian Journal of Psychiatry, AHEAD.

  74. Forman, M. (1975). One Flew Over the Cuckoo’s Nest. Warner.

  75. Fornito, A., Yücel, M., Wood, S. J., Adamson, C., Velakoulis, D., Saling, M. M., McGorry, P. D., & Pantelis, C. (2008). Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Human Brain Mapping, 29(4), 478–489.

  76. Fors, B. M., Isacson, D., Bingefors, K., & Widerlöv, B. (2007). Mortality among persons with schizophrenia in Sweden: An epidemiological study. Nordic Journal of Psychiatry, 61(4), 252–259.

  77. Foussias, G., & Remington, G. (2010). Antipsychotics and schizophrenia: From efficacy and effectiveness to clinical decision-making. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 55(3), 117–125.

  78. Frankle, W. G., Lombardo, I., Kegeles, L. S., Slifstein, M., Martin, J. H., Huang, Y., Hwang, D.-R., Reich, E., Cangiano, C., Gil, R., Laruelle, M., & Abi-Dargham, A. (2006). Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: A positron emission tomography imaging study with [11C] WAY 100635. Psychopharmacology, 189(2), 155–164.

  79. Fröhlich, F., & Lustenberger, C. (2020). Neuromodulation of sleep rhythms in schizophrenia: Towards the rational design of non-invasive brain stimulation. Schizophrenia Research.

  80. Fromm-Reichmann, F. (1939). Transference problems in schizophrenics. The Psychoanalytic Quarterly, 8, 412–426.

  81. Fu, S., Czajkowski, N., & Torgalsbøen, A.-K. (2019). Cognitive, work, and social outcomes in fully recovered first-episode schizophrenia: On and off antipsychotic medication. Psychiatry: Interpersonal and Biological Processes.

  82. Garfield, D., & Mackler, D. (2013). Beyond Medication: Therapeutic Engagement and the Recovery from Psychosis. Routledge.

  83. Garver, D. L., Holcomb, J. A., & Christensen, J. D. (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry, 61(12), 964–974.

  84. Gault, J. M., Davis, R., Cascella, N. G., Saks, E. R., Corripio-Collado, I., Anderson, W. S., Olincy, A., Thompson, J. A., Pomarol-Clotet, E., Sawa, A., Daskalakis, Z. J., Lipsman, N., & Abosch, A. (2018). Approaches to neuromodulation for schizophrenia. Journal of Neurology, Neurosurgery & Psychiatry, 89(7), 777–787.

  85. Gazdag, G., & Ungvari, G. S. (2019). Electroconvulsive therapy: 80 years old and still going strong. World Journal of Psychiatry, 9(1), 1–6.

  86. Gearon, J. S., Bellack, A. S., Rachbeisel, J., & Dixon, L. (2001). Drug-use behavior and correlates in people with schizophrenia. Addictive Behaviors, 26(1), 51–61.

  87. Gibbs, P. L. (2007). The primacy of psychoanalytic intervention in recovery from the psychoses and schizophrenias. The Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 35(2), 287–312.

  88. Gil, A., Gama, C. S., de Jesus, D. R., Lobato, M. I., Zimmer, M., & Belmonte-de-Abreu, P. (2009). The association of child abuse and neglect with adult disability in schizophrenia and the prominent role of physical neglect. Child Abuse & Neglect, 33(9), 618–624.

  89. Gilmore, J. H. (2010). Understanding what causes schizophrenia: A developmental perspective. The American Journal of Psychiatry, 167(1), 8–10.

  90. Gilmour, G., Dix, S., Fellini, L., Gastambide, F., Plath, N., Steckler, T., Talpos, J., & Tricklebank, M. (2012). NMDA receptors, cognition and schizophrenia – testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology, 62(3), 1401–1412.

  91. Giovachinni, P., & Boyer, B. L. (1980). Psychoanalytic Treatment of Schizophrenic Borderline and Characterological Disorders(Enlarged 2nd Edition). Jason Aronson, Inc.

  92. Girdler, S. J., Confino, J. E., & Woesner, M. E. (2019). Exercise as a Treatment for Schizophrenia: A Review. Psychopharmacology Bulletin, 49(1), 56–69.

  93. Gold, C. (2015). Dose and effect in CBT for schizophrenia. The British Journal of Psychiatry, 207(3), 269–273.

  94. González de Chávez, M. (2009). Treatment of psychoses before the twentieth century. In Y. O. Alanen, M. González de Chávez, A.-L. S. Silver, & B. Martindale (Eds.), Psychotherapeutic approaches to schizophrenic psychoses: Past, present and future. (2009-10328-002; pp. 10–22). Routledge/Taylor & Francis Group.

  95. Gonzalez-Flores, B. L. (2020). Impact of independent exercise on recovery, well-being, and motivation among individuals with schizophrenia (2020-28121-043; Issues 4-B). ProQuest Information & Learning.

  96. Gottdiener, W. H. (2006). Individual psychodynamic psychotherapy of schizophrenia: Empirical evidence for the practicing clinician. Psychoanalytic Psychology, 23(3), 583–589.

  97. Gray, L., Scarr, E., & Dean, B. (2006). Serotonin 1a receptor and associated G-protein activation schizophrenia and bipolar disorder. Psychiatry Research, 143(2), 111–120.

  98. Green, M. F., Horan, W. P., & Lee, J. (2019). Nonsocial and social cognition in schizophrenia: Current evidence and future directions. World Psychiatry, 18(2), 146–161.

  99. Grignon, S., & Trottier, M. (2005). Capgras Syndrome in the Modern Era: Self Misidentification on an ID Picture. The Canadian Journal of Psychiatry / La Revue Canadienne de Psychiatrie, 50(1), 74–75.

  100. Grotstein, J. S. (2001). A rationale for the psychoanalytically informed psychotherapy of schizophrenia and other psychoses: Towards the concept of “rehabilitative psychoanalysis.” A Language for Psychosis: Psychoanalysis of Psychotic States., 9–26.

  101. Grotstein, J. S. (2003). Towards the concept of “rehabilitative psychoanalytic psychotherapy” in the treatment of schizophrenia. Preventive Strategies for Schizophrenic Disorders: Basic Principles, Opportunities and Limits., 350–365.

  102. Gründer, G., & Cumming, P. (2016). The dopamine hypothesis of schizophrenia: Current status. In T. Abel & T. Nickl-Jockschat (Eds.), The neurobiology of schizophrenia. (2016-43112-007; pp. 109–124). Elsevier Academic Press.

  103. Gur, R. E., Loughead, J., Kohler, C. G., Elliott, M. A., Lesko, K., Ruparel, K., Wolf, D. H., Bilker, W. B., & Gur, R. C. (2007). Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Archives of General Psychiatry, 64(12), 1356–1366.

  104. Hadar, R., Bikovski, L., Soto-Montenegro, M. L., Schimke, J., Maier, P., Ewing, S., Voget, M., Wieske, F., Götz, T., Desco, M., Hamani, C., Pascau, J., Weiner, I., & Winter, C. (2018). Early neuromodulation prevents the development of brain and behavioral abnormalities in a rodent model of schizophrenia. Molecular Psychiatry, 23(4), 943–951.

  105. Hagiwara, H., Fujita, Y., Ishima, T., Kunitachi, S., Shirayama, Y., Iyo, M., & Hashimoto, K. (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: Role of serotonin 5-HT-sub(1A) receptors. European Neuropsychopharmacology, 18(6), 448–454.

  106. Hashimoto, T., Bazmi, H. H., Mirnics, K., Wu, Q., Sampson, A. R., & Lewis, D. A. (2008). Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. American Journal of Psychiatry, 165(4), 479–489.

  107. Healy, D. (2006). Neuroleptics and mortality: A 50-year cycle: Invited commentary on... schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 128.

  108. Hendrick, I. (1928). Encephalitis lethargica and the interpretation of mental disease. American Journal of Psychiatry, 7, 989–1014.

  109. Henssler, J., Brandt, L., Müller, M., Liu, S., Montag, C., Sterzer, P., & Heinz, A. (2020). Migration and schizophrenia: Meta-analysis and explanatory framework. European Archives of Psychiatry and Clinical Neuroscience, 270(3), 325–335.

  110. Hoeffding, L. K., Rosengren, A., Thygesen, J. H., Schmock, H., Werge, T., & Hansen, T. (2017). Evaluation of shared genetic susceptibility loci between autoimmune diseases and schizophrenia based on genome-wide association studies. Nordic Journal of Psychiatry, 71(1), 20–25.

  111. Hong, J., & Bang, M. (2020). Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Clinical Psychopharmacology and Neuroscience, 18(1), 10–24.

  112. Høyersten, J. G. (1996). [Possessed! Some historical, psychiatric and curent moments of demonic possession]. Tidsskrift for Den Norske Laegeforening: Tidsskrift for Praktisk Medicin, Ny Raekke, 116(30), 3602–3606.

  113. Hua, M., Peng, Y., Zhou, Y., Qin, W., Yu, C., & Liang, M. (2020). Disrupted pathways from limbic areas to thalamus in schizophrenia highlighted by whole-brain resting-state effective connectivity analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 99, 109837.

  114. İpçi, K., Yildiz, M., İncedere, A., Kiras, F., Esen, D., & Gürcan, M. B. (2020). Subjective recovery in patients with schizophrenia and related factors. Community Mental Health Journal.

  115. Janssen, I., Krabbendam, L., Bak, M., Hanssen, M., Vollebergh, W., de Graaf, R., & van Os, J. (2004). Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatrica Scandinavica, 109(1), 38–45.

  116. Jauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. The British Journal of Psychiatry, 204(1), 20–29.

  117. Jentsch, J. D., & Roth, R. H. (1999). The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20(3), 201–225.

  118. Jia, J., Shen, J., Liu, F.-H., Wong, H. K., Yang, X.-J., Wu, Q.-J., Zhang, H., Wang, H.-N., Tan, Q.-R., & Zhang, Z.-J. (2019). Effectiveness of electroacupuncture and electroconvulsive therapy as additional treatment in hospitalized patients with schizophrenia: A retrospective controlled study. Frontiers in Psychology, 10.

  119. Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188(2), 122–127.

  120. Joyal, C. C., Hallé, P., Lapierre, D., & Hodgins, S. (2003). Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophrenia Research, 63(3), 297–299.

  121. Juckel, G., & Hoffmann, K. (2018). [The Indian Ayurveda medicine-a meaningful supplement to psychiatric treatment?]. Der Nervenarzt, 89(9), 999–1008.

  122. Jung, C. G. (1925). The content of the psychoses. In J. S. Van Teslaar (Ed.), An outline of psychoanalysis.(2006-21557-012; pp. 255–271). Modern Library.

  123. Kane, J. M., & Leucht, S. (2008). Unanswered questions in schizophrenia clinical trials. Schizophrenia Bulletin, 34(2), 302–309.

  124. Kapelski, P., Hauser, J., Dmitrzak-Weglarz, M., Skibinska, M., Slopien, A., Kaczmarkiewicz-Fass, M., Rajewska, A., Gattner, K., & Czerski, P. M. (2006). Brak asocjacji pomiedzy polimorfizmem insercyjno-delecyjnym promotorowego odcinka genu transportera serotoniny a schizofrenia. Psychiatria Polska, 40(5), 925–935.

  125. Kapsambelis, V. (2019). Psychoanalytic approaches to psychotic disorders in a public mental health system. British Journal of Psychotherapy, 35(4), 577–585.

  126. Kelly, D. L., Rowland, L. M., Patchan, K. M., Sullivan, K., Earl, A., Raley, H., Liu, F., Feldman, S., & McMahon, R. P. (2016). Schizophrenia clinical symptom differences in women vs men with and without a history of childhood physical abuse. Child and Adolescent Psychiatry and Mental Health, 10.

  127. Kesey, K. (1963). One Flew Over the Cuckoo’s Nest. Berkley.

  128. Khandaker, G. M., Zimbron, J., Dalman, C., Lewis, G., & Jones, P. B. (2012). Childhood infection and adult schizophrenia: A meta-analysis of population-based studies. Schizophrenia Research, 139(1–3), 161–168.

  129. Kim, H., Kim, D., & Kim, S. H. (2018). Association of types of delusions and hallucinations with childhood abuse and neglect among inpatients with schizophrenia in South Korea: A preliminary study. Psychosis: Psychological, Social and Integrative Approaches, 10(3), 208–212.

  130. Kline, J., Becker, J., & Giese, C. (1992). Psychodynamic interventions revisited: Options for the treatment of schizophrenia. Psychotherapy: Theory, Research, Practice, Training, 29(3), 366–377.

  131. Knight, J. G. (1982). Dopamine-receptor-stimulating autoantibodies: A possible cause of schizophrenia. Lancet (London, England), 2(8307), 1073–1076.

  132. Knight, J. G., Menkes, D. B., Highton, J., & Adams, D. D. (2007). Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Molecular Psychiatry, 12(5), 424–431.

  133. Koch, E., Rosenthal, B., Lundquist, A., Chen, C.-H., & Kauppi, K. (2020). Interactome overlap between schizophrenia and cognition. Schizophrenia Research, S0920996420303467.

  134. Kohler, C. G., Loughead, J., Ruparel, K., Indersmitten, T., Barrett, F. S., Gur, R. E., & Gur, R. C. (2008). Brain activation during eye gaze discrimination in stable schizophrenia. Schizophrenia Research, 99(1), 286–293.

  135. Kortegaard, H. M. (1993). Music